SCHEMBL7705061

SCHEMBL7705061

COc1ccccc1N1CCN(CC(O)COc2cc(C)c(OCc3ccccc3)c(OC)c2OC)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.64
KMT2A Q03164 4/20 0.64
MAPT P10636 8/20 0.62
ALDH1A1 P00352 3/20 0.62
ABCB1 P08183 5/20 0.59
LMNA P02545 6/20 0.59
MAPK1 P28482 2/20 0.59
TDP1 Q9NUW8 2/20 0.59
TP53 P04637 2/20 0.59
KDM4E B2RXH2 2/20 0.59
HIF1A Q16665 2/20 0.59
KCNH2 Q12809 2/20 0.59
NR1I2 O75469 1/20 0.59
NR3C1 P04150 1/20 0.59
ADRB1 P08588 1/20 0.59
HTR1A P08908 1/20 0.59
ADRA2A P08913 1/20 0.59
DRD2 P14416 1/20 0.59
ADRA2B P18089 1/20 0.59
ADRA2C P18825 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7974694 0.90 MAPT (0.63) MEN1KMT2AMAPTALDH1A1ABCB1
Hydrochloric Acid SCHEMBL7713479 0.89 MEN1 (0.64) MEN1KMT2AMAPTALDH1A1ABCB1
SCHEMBL7705100 0.89 MAPT (0.69) MEN1KMT2AMAPTALDH1A1ABCB1
SCHEMBL9349189 0.83 MAPT (0.74) MEN1KMT2AMAPTALDH1A1ABCB1
SCHEMBL7711599 0.81 MEN1 (0.70) MEN1KMT2AMAPTALDH1A1ABCB1
SCHEMBL7711707 0.80 MEN1 (0.74) MEN1KMT2AMAPTALDH1A1ABCB1
SCHEMBL7708508 0.80 MEN1 (0.81) MEN1KMT2AMAPTALDH1A1ABCB1
SCHEMBL7711678 0.79 TP53 (0.61) MEN1KMT2AMAPTALDH1A1ABCB1
Hydrochloric Acid SCHEMBL7707631 0.79 MEN1 (0.83) MEN1KMT2AMAPTALDH1A1ABCB1
Hydrochloric Acid SCHEMBL7710962 0.79 MEN1 (0.76) MEN1KMT2AMAPTALDH1A1ABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6358515-B2 ANTIHYPERTENSIVE PHARMACEUTICAL COMPOSITION; TREATMENT OF GLAUCOMA SENJU PHARMACEUTICAL CO., LTD. (JP) 2002-03-19 US claimed
US-20010008893-A1 HYDROQUINONE DERIVATIVES SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-07-19 US claimed
EP-0972766-A1 HYDROQUINONE DERIVATIVES Senju Pharmaceutical Co., Ltd. (JP) 2000-01-19 EP claimed
US-6358515-B2 ANTIHYPERTENSIVE PHARMACEUTICAL COMPOSITION; TREATMENT OF GLAUCOMA SENJU PHARMACEUTICAL CO., LTD. (JP) 2002-03-19 US disclosed
US-20010008893-A1 HYDROQUINONE DERIVATIVES SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-07-19 US disclosed
EP-0972766-A1 HYDROQUINONE DERIVATIVES Senju Pharmaceutical Co., Ltd. (JP) 2000-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010008893-A1 HYDROQUINONE DERIVATIVES REN, AGTR1, AGTR2 MEN1 2775/4885KMT2A 2128/4885MAPT 4729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.